LY-301317

{{Infobox drug | IUPAC_name = (2S)-2-[[4-[2-(3,4-dihydroxyphenyl)ethyl]phenoxy]methyl]morpholine | image = | width = | alt = | legal_status = | routes_of_administration = | bioavailability = | protein_bound = | metabolism = | elimination_half-life = | excretion = | CAS_number = 123456-78-9 | ATC_prefix = | ATC_suffix = | PubChem = 123456 | DrugBank = | ChemSpiderID = 123456 | UNII = | KEGG = | ChEBI = | ChEMBL = | synonyms = }}

LY-301317 is a chemical compound that has been studied for its potential effects on lipid metabolism and cholesterol levels. It is classified as a hypolipidemic agent, which means it is intended to lower lipid levels in the blood. This compound was developed by Eli Lilly and Company as part of their research into treatments for hyperlipidemia and related cardiovascular conditions.

Chemical Structure and Properties

LY-301317 is a synthetic compound with a complex chemical structure. It is characterized by the presence of a morpholine ring, which is a common feature in many pharmacologically active compounds. The compound also contains a phenoxy group, which is linked to a dihydroxyphenyl moiety. This structure is believed to contribute to its biological activity.

Mechanism of Action

The exact mechanism of action of LY-301317 is not fully understood, but it is thought to involve the modulation of lipid metabolism pathways. It may act by inhibiting certain enzymes involved in the synthesis of cholesterol and triglycerides, thereby reducing their levels in the bloodstream. This action could potentially lead to a decrease in the risk of atherosclerosis and other cardiovascular diseases.

Pharmacokinetics

The pharmacokinetic profile of LY-301317 includes its absorption, distribution, metabolism, and excretion. Studies have shown that it is absorbed into the bloodstream after oral administration. It is then distributed throughout the body, where it exerts its effects on lipid metabolism. The compound is metabolized in the liver, and its metabolites are excreted primarily through the kidneys.

Clinical Studies

Several clinical studies have been conducted to evaluate the efficacy and safety of LY-301317. These studies have focused on its ability to lower cholesterol and triglyceride levels in patients with hyperlipidemia. Results have shown that LY-301317 can effectively reduce lipid levels, although its long-term safety and efficacy require further investigation.

Potential Side Effects

As with any pharmacological agent, LY-301317 may cause side effects. Common side effects observed in clinical trials include gastrointestinal disturbances, such as nausea and diarrhea. More serious side effects, although rare, may include liver dysfunction and muscle pain. Patients taking LY-301317 should be monitored regularly for any adverse effects.

Regulatory Status

As of the latest information available, LY-301317 has not been approved for clinical use by major regulatory agencies such as the FDA or EMA. It remains an investigational compound, and further research is needed to determine its potential as a therapeutic agent.

Also see

• Hyperlipidemia
• Cholesterol
• Cardiovascular disease
• Lipid metabolism
• Hypolipidemic agent